Could very well depend on current trials. In my view the whole vet first strategy has backfired in the long run, even if it resulted in the novelty of an FDA approval for an Aussie pharmaceutical from a small co. Stelfonta struggling likely because its 'challenging' in the way it presents during treatment (ghastly wounds that nevertheless heal quickly mostly/ often?). Should have pkaced much more emphasis on the wound healing + human cancers. Not as sexy as cancer I guess (droll). Instead many years later in 2024 just starting prelim trials. Cant just blame the scientists, previous management set the course, and their reputations have been somewhat sullied since. However, still seem to be complacent as ever towards long suffering investors. Have perhaps convinced themselves that we are no doubt cognizant of the risks in investing and they are not culpable...despite off-loading millions of shares (@$1) at a critical juncture.
